Prescient Therapeutics (ASX:PTX) to progress deep cancer-treatment pipeline with capital raise
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan...
We think that it's fair to say that the possibility of finding fantastic multi-year winners...
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum...
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell...
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.